BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early-stage science into medicines that treat disease at its source.
Founded in 2015 by a team of industry veterans, the company has built a robust portfolio of eighteen transformative drugs ranging from pre-clinical to late-stage development in multiple therapeutic areas including oncology, cardiology, dermatology, and rare disease. BridgeBio holds each drug candidate in a distinct subsidiary company to maximize management focus and financial flexibility.
BridgeBio’s focus on scientific excellence and rapid execution aim to translate today’s discoveries into tomorrow’s medicines.